Compare Aehr Test Systems (AEHR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aehr Test Systems vs Neurocrine Biosciences Inc — how do they compare? Aehr Test Systems trades at $121.21 (market cap $3.82B), while Neurocrine Biosciences Inc trades at $152.14 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.3× Aehr Test Systems's market cap, and Aehr Test Systems is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| AEHR | NBIX | |
|---|---|---|
Market Cap | $3.82B | $16.46B |
Sector | Technology | Health |
52-Week High | $117.18 | $185.50 |
52-Week Low | $17.38 | $123.10 |
Enterprise Value | $3.72B | $16.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
